Gene transfer of insulin-like growth factor-I providing neuroprotection after spinal cord injury in rats

J Neurosurg Spine. 2007 Jan;6(1):35-46. doi: 10.3171/spi.2007.6.1.35.

Abstract

Object: Insulin-like growth factor-I (IGF-I) has been shown to be a potent neurotrophic factor that promotes the growth of projection neurons, dendritic arborization, and synaptogenesis. Its neuroprotective roles may be coordinated by activation of Akt, inhibition of glycogen synthase kinase-3beta (GSK-3beta), and thus inhibition of tau phosphorylation. The authors investigated the role and mechanism of IGF-I gene transfer after spinal cord injury (SCI).

Methods: Studies were performed in 40 male Sprague-Dawley rats after spinal cord hemisection. The authors conducted hydrodynamics-based gene transfection in which an IGF-I plasmid was rapidly injected into the rat's tail vein 30 minutes after SCI. The animals were randomly divided into four groups: Group I, sham operated; Group II, SCI treated with pCMV-IGF-I gene; Group III, SCI treated with vehicle pCMV-LacZ gene; and Group IV, SCI only. The results showed that IGF-I gene transfer promoted motor recovery, antiinflammatory responses, and antiapoptotic effects after SCI. Using techniques of Western blotting and immunohistochemistry, the authors assessed the mechanism of IGF-I gene transfer after SCI in terms of activation of Akt, inhibition of GSK-3beta, attenuation of p35, and inhibition of tau phosphorylation. Moreover, they found that IGF-I gene transfer could block caspase-9 cleavage, increase Bcl-2 formation, and thus inhibit apoptosis after SCI.

Conclusions: The intravenous administration of IGF-I after SCI activated Akt, attenuated GSK-3beta, inhibited p35 activation, diminished tau hyperphosphorylation, ended microglia and astrocyte activation, inhibited neuron loss, and significantly improved neurological dysfunction. Furthermore, IGF-I attenuated caspase-9 cleavage, increased Bcl2, and thus inhibited apoptosis after SCI.

Publication types

  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Astrocytes / drug effects
  • Blotting, Western
  • Caspase 9 / drug effects
  • Dendrites / drug effects
  • Dendrites / pathology
  • Disease Models, Animal
  • Gene Transfer Techniques / instrumentation*
  • Genes, bcl-2 / genetics
  • Genes, p53 / genetics
  • Glycogen Synthase Kinase 3 / antagonists & inhibitors
  • Glycogen Synthase Kinase 3 beta
  • Insulin-Like Growth Factor I / genetics*
  • Insulin-Like Growth Factor I / pharmacology
  • Insulin-Like Growth Factor I / therapeutic use*
  • Lac Operon / genetics
  • Male
  • Microglia / drug effects
  • Neurons / drug effects
  • Neurons / pathology
  • Neuroprotective Agents / pharmacology
  • Neuroprotective Agents / therapeutic use*
  • Phosphorylation / drug effects
  • Plasmids / genetics
  • Random Allocation
  • Rats
  • Rats, Sprague-Dawley
  • Spinal Cord Injuries / genetics*
  • Spinal Cord Injuries / pathology
  • Spinal Cord Injuries / therapy*
  • Synapses / drug effects
  • Synapses / pathology
  • tau Proteins / genetics

Substances

  • Neuroprotective Agents
  • tau Proteins
  • Insulin-Like Growth Factor I
  • Glycogen Synthase Kinase 3 beta
  • Gsk3b protein, rat
  • Glycogen Synthase Kinase 3
  • Caspase 9